Diagnosis and treatment of alzheimer's disease
OwnerJonas Nilsson, Adnan Halim +5inventors
InventorsJonas Nilsson, Adnan Halim, Göran Larson, Kaj Blennow, Gunnar Brinkmalm, Erik Portelius, Henrik Zetterberg
Life of this patent
Estimating the term…
Abstract
Methods are provided for the prevention, treatment and diagnosis of Alzheimer's disease, based on the glycosylation pattern of amyloid-beta peptides in body fluids and tissues.
Claims26
A method for diagnosing or prognosing Alzheimer's disease in a subject, or determining whether a subject is at increased risk of developing Alzheimer's disease, comprising:
- a. determining the amounts of Abeta peptide with O-linked Tyr10 glycosylation in a sample;
- and
- b. comparing said level to a reference value representing a known disease or health status, wherein a varied level in said sample relative to a said reference value representing a known health status indicates a diagnosis, or prognosis, or increased risk of Alzheimer's disease.
6-7. (canceled)
(canceled)
12-14. (canceled)
16-17. (canceled)
The method according to claim 17 wherein the binding ligand is biotin;
- the capture ligand is the anti-human amyloid beta (N) 82E1 mouse IgG monoclonal antibody;
- the detectable label conjugated to a moiety with affinity for the binding ligand is peroxidase conjugated to streptavidin;
- and the quantifying of the detectable label is done by optically reading the signal output generated by a peroxidase-TMB reaction at 450 nm.
The method of claim 17 wherein the capture ligand has affinity for the combination of O-glycosylation at Tyr10 on Abeta and Abeta peptide backbone.
21-22. (canceled)
24-27. (canceled)
A method of generating antibodies, comprising using one or more Tyr10 glycosylated Abeta peptides or Tyr10 glycosylated APP.
An antibody or antibody-like molecule against one or more Tyr′ 0 glycosylated Abeta peptides or Tyr10 glycosylated APP.
32-37. (canceled)
Dependencies are inferred from the claim text.